Get the Daily Brief
Latest Biotech News
Third CRL sinks Outlook’s bevacizumab outlook — stock tumbles
Outlook Therapeutics received a third FDA complete response letter for ONS‑5010, its bevacizumab formulation for wet age‑related macular degeneration; the company’s stock plunged after the...
Nido Biosciences closes after mid‑stage failure in rare neurology trial
Nido Biosciences announced it will shut down after its lead neurology candidate failed to move the needle in a phase 2 study, ending five years of operation. The company cited the midstage readout...
Inherited variant slows clonal hematopoiesis and lowers leukemia risk — Science
A Science paper from Vijay G. Sankaran’s lab reports a rare noncoding variant, rs17834140‑T, that reduces clonal hematopoiesis of indeterminate potential (CHIP) and lowers blood cancer risk by...
Venetoclax resistance tackled: palbociclib combination shows activity in AML models
Researchers at Oregon Health & Science University reported that combining venetoclax with the CDK4/6 inhibitor palbociclib produced stronger and more durable anti‑leukemia activity than venetoclax...
Base editors... CHANGE-seq-BE maps off-targets
Researchers published a tailored pipeline, CHANGE-seq-BE, that profiles base-editor–induced off-target activity across genomes with high sensitivity. The method, reported in Nature Biotechnology,...
Single-strand deaminases... RNA editing scales
Two parallel reports in Nature Biotechnology describe new single-strand deaminase platforms that expand programmable RNA editing. One study introduces a single-strand deaminase–assisted system...
Antifungal micelles... combination delivery reduces toxicity
Nature Biotechnology published complementary preclinical advances showing micelle-based delivery can both potentiate antifungal drugs and reduce host toxicity. One study engineered a host-defense...
SMRTnet... predictive RNA–small-molecule platform
Researchers introduced SMRTnet, a deep-learning platform that predicts small-molecule–RNA interactions without requiring RNA tertiary structures. The model fuses large language models with graph...
Holiday licensing... AbbVie, Gilead pick up clinical-stage oncology assets
During the year-end period, large pharmas secured clinical-stage oncology programs: AbbVie and Gilead announced separate deals to add targeted cancer drugs to their pipelines. AbbVie paid a large...
Transcenta licenses continuous biomanufacturing to EirGenix
Transcenta Therapeutics struck a non-exclusive licensing and collaboration agreement to grant EirGenix access to its HiCB (highly intensified continuous bioprocessing) platform for continuous...
Third FDA CRL... Outlook’s bevacizumab program collapses
Outlook Therapeutics received a third complete response letter from the U.S. FDA for ONS-5010, its bevacizumab formulation for wet age-related macular degeneration, prompting a sharp share-price...
Ultragenyx halts brittle-bone program — prepares major cost cuts
Ultragenyx reported failure of two phase 3 trials in brittle-bone disease and said it will execute significant cost reductions. The company will reassess its pipeline priorities and implement...
Nido Biosciences folds after midstage failure
Neuro biotech Nido Biosciences announced closure after its lead neurological candidate failed to show benefit in a phase 2 study. The company will wind down operations after five years and...
NIH leadership churn... NINDS director exits
The National Institutes of Health saw further leadership turnover as NINDS director Walter Koroshetz, M.D., exited, deepening interim management across institutes. The departure leaves half of NIH...
Holiday licensing spree: AbbVie, Gilead pick up clinical cancer assets
AbbVie and Gilead executed late‑December licensing deals that immediately reshaped their oncology pipelines. AbbVie paid an up‑front sum to secure ex‑China rights to Zelgen Biopharmaceuticals’...
Transcenta licenses continuous biomanufacturing to EirGenix — CDMO pact
Transcenta Therapeutics granted EirGenix a non‑exclusive license to its highly intensified continuous bioprocessing (HiCB) platform, transferring process documentation, regulatory support packages...
Third FDA CRL tanks Outlook’s bevacizumab copy: Stock collapses
Outlook Therapeutics received a third complete response letter (CRL) from the FDA for ONS‑5010, its bevacizumab biosimilar candidate for wet age‑related macular degeneration, triggering a steep...
Ultragenyx to cut costs after phase 3 brittle‑bone failures
Ultragenyx Pharmaceuticals reported the failure of two late‑stage trials in brittle‑bone disease and announced plans for significant cost reductions. The company is preparing a major spending...
Neuro biotech Nido shuts after midstage flop — five‑year run ends
Nido Biosciences closed operations after its lead neurological candidate failed to produce meaningful benefit in a midstage (phase 2) study. The company — founded to develop therapies for a rare...
Single‑strand deaminases push RNA editing toward multiplex control
Two independent reports describe single‑strand deaminase platforms that enable programmable and multiplexed RNA editing across transcripts. One study presents an adjustable RNA information...